Roth Capital Has Negative View of Globus Medical Q1 Earnings

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Roth Capital decreased their Q1 2025 EPS estimates for shares of Globus Medical in a note issued to investors on Thursday, March 13th. Roth Capital analyst J. Wittes now expects that the medical device company will earn $0.71 per share for the quarter, down from their prior forecast of $0.74. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Roth Capital also issued estimates for Globus Medical’s Q4 2025 earnings at $1.01 EPS.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.10. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The business had revenue of $657.29 million during the quarter, compared to the consensus estimate of $646.19 million.

Other equities research analysts also recently issued reports about the stock. Barclays raised their target price on shares of Globus Medical from $100.00 to $103.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Bank of America upgraded shares of Globus Medical from an “underperform” rating to a “neutral” rating and raised their target price for the company from $80.00 to $97.00 in a research note on Thursday, January 9th. Truist Financial raised their target price on shares of Globus Medical from $85.00 to $90.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. BTIG Research raised their price objective on shares of Globus Medical from $87.00 to $91.00 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Finally, Canaccord Genuity Group raised their price objective on shares of Globus Medical from $92.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $97.82.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $71.21 on Friday. Globus Medical has a 52-week low of $49.33 and a 52-week high of $94.93. The company has a market capitalization of $9.79 billion, a P/E ratio of 94.94, a price-to-earnings-growth ratio of 1.61 and a beta of 1.19. The company has a 50-day simple moving average of $84.86 and a 200 day simple moving average of $79.69.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in GMED. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Globus Medical in the fourth quarter valued at approximately $16,757,000. Polar Asset Management Partners Inc. increased its stake in Globus Medical by 73.6% in the fourth quarter. Polar Asset Management Partners Inc. now owns 452,274 shares of the medical device company’s stock valued at $37,408,000 after acquiring an additional 191,700 shares during the last quarter. Burgundy Asset Management Ltd. increased its stake in Globus Medical by 1.7% in the fourth quarter. Burgundy Asset Management Ltd. now owns 2,618,108 shares of the medical device company’s stock valued at $216,544,000 after acquiring an additional 43,330 shares during the last quarter. PharVision Advisers LLC bought a new position in Globus Medical in the fourth quarter valued at approximately $339,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Globus Medical by 9.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 319,500 shares of the medical device company’s stock valued at $26,426,000 after acquiring an additional 28,330 shares during the last quarter. 95.16% of the stock is owned by institutional investors.

Insider Transactions at Globus Medical

In other news, CFO Keith W. Pfeil sold 14,167 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $88.29, for a total transaction of $1,250,804.43. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 18.54% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.